42.48
0.99 (2.39%)
| Penutupan Terdahulu | 41.49 |
| Buka | 41.48 |
| Jumlah Dagangan | 505,457 |
| Purata Dagangan (3B) | 513,930 |
| Modal Pasaran | 2,138,570,624 |
| Harga / Pendapatan (P/E TTM) | 849.60 |
| Harga / Pendapatan (P/E Ke hadapan) | 105.26 |
| Harga / Jualan (P/S) | 8.28 |
| Harga / Buku (P/B) | 6.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
| Margin Keuntungan | 4.37% |
| Margin Operasi (TTM) | 24.52% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 52.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.09% |
| Nisbah Semasa (MRQ) | 4.23 |
| Aliran Tunai Operasi (OCF TTM) | 58.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.76 M |
| Pulangan Atas Aset (ROA TTM) | 0.72% |
| Pulangan Atas Ekuiti (ROE TTM) | 4.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Vericel Corporation | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.70 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.03% |
| % Dimiliki oleh Institusi | 107.58% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 67.00 (Stephens & Co., 57.72%) | Beli |
| Median | 60.00 (41.24%) | |
| Rendah | 51.00 (Truist Securities, 20.06%) | Beli |
| Purata | 59.33 (39.67%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 45.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stephens & Co. | 22 May 2025 | 67.00 (57.72%) | Beli | 42.48 |
| Truist Securities | 11 Apr 2025 | 51.00 (20.06%) | Beli | 41.25 |
| 03 Mar 2025 | 61.00 (43.60%) | Beli | 49.51 | |
| HC Wainwright & Co. | 28 Feb 2025 | 60.00 (41.24%) | Beli | 51.29 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 May 2025 | Pengumuman | Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance |
| 07 May 2025 | Pengumuman | Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 |
| 24 Apr 2025 | Pengumuman | Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 |
| 04 Mar 2025 | Pengumuman | Vericel to Present at Multiple Upcoming Investor Conferences |
| 27 Feb 2025 | Pengumuman | Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |